GSK acquires Aiolos Bio and with it AIO 001, a long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody
GSK plc and Aiolos Bio, Inc. announced that they have entered into an agreement under which GSK will acquire Aiolos, a clinical-stage biopharmaceutical company focused on addressing the unmet treatment needs of patients with certain respiratory and inflammatory conditions, for a $1 billion upfront payment and up to $400 million in certain success-based regulatory milestone payments
The acquisition provides GSK with access to Aiolos’ AIO 001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody ready to enter phase II clinical development for the treatment of adult patients with asthma, with potential for additional indications including chronic rhinosinusitis with nasal polyps. AIO 001 was exclusively licensed to Aiolos outside of Greater China by Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui). Targeting the TSLP pathway addresses a key driver of the inflammatory response in major allergic and inflammatory diseases. TSLP is a clinically validated target in the treatment of asthma regardless of biomarker status. Early studies of AIO-001 have shown initial safety, tolerability, pharmacokinetics, and biological activity in healthy volunteers and asthma patients. Additionally, AIO-001 has potential to be administered every six months due to its enhanced potency and half-life extension technology, which could redefine the standard-of-care.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins